論文・総説 - 玉村　啓和

分割表示  318 件中 161 - 180 件目  ／  全件表示 >>

  1. Tamamura H, Araki T, Ueda S, Wang Z, Oishi S, Esaka A, Trent JO, Nakashima H, Yamamoto N, Peiper SC, Otaka A, Fujii N. Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds. J Med Chem. 2005.05; 48 (9): 3280-3289. ( PubMed, DOI )

  2. Zannettino AC, Farrugia AN, Kortesidis A, Manavis J, To LB, Martin SK, Diamond P, Tamamura H, Lapidot T, Fujii N, Gronthos S. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res. 2005.03; 65 (5): 1700-1709. ( PubMed, DOI )

  3. Percherancier Y, Berchiche YA, Slight I, Volkmer-Engert R, Tamamura H, Fujii N, Bouvier M, Heveker N. Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homo- and heterodimers. J Biol Chem. 2005.03; 280 (11): 9895-9903. ( PubMed, DOI )

  4. Piovan E, Tosello V, Indraccolo S, Cabrelle A, Baesso I, Trentin L, Zamarchi R, Tamamura H, Fujii N, Semenzato G, Chieco-Bianchi L, Amadori A. Chemokine receptor expression in EBV-associated lymphoproliferation in hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation. Blood. 2005.02; 105 (3): 931-939. ( PubMed, DOI )

  5. Nameki D, Kodama E, Ikeuchi M, Mabuchi N, Otaka A, Tamamura H, Ohno M, Fujii N, Matsuoka M. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions. J Virol. 2005.01; 79 (2): 764-770. ( PubMed, DOI )

  6. Tamamura H, Hiramatsu K, Ueda S, Wang Z, Kusano S, Terakubo S, Trent JO, Peiper SC, Yamamoto N, Nakashima H, Otaka A, Fujii N. Stereoselective synthesis of [L-Arg-L/D-3-(2-naphthyl)alanine]-type (E)-alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogues of the CXCR4 antagonist FC131. J Med Chem. 2005.01; 48 (2): 380-391. ( PubMed, DOI )

  7. Ayumu Niida, Shinya Oishi, Yoshikazu Sasaki, Makiko Mizumoto, Hirokazu Tamamura, Nobutaka Fujii & Akira Otaka. Facile Access to (Z)-Alkene-containing Diketopiperazine Mimetics Utilizing Organocopper-mediated Anti-SN2' Reactions. Tetrahedron Lett.. 2005; 46 4183-4186.

  8. Jayendra B. Bhonsle, Zi-xuan Wang, Hirokazu Tamamura, Nobutaka Fujii, Stephen C. Peiper & John O. Trent. A Simple, Automated Quasi-4D-QSAR, Quasi-multi Way PLS Approach to Develop Highly Predictive QSAR Models for Highly Flexible CXCR4 Inhibitor Cyclic Peptide Ligands Using Scripted Common Molecular Modeling Tools. QSAR Comb. Sci.. 2005; 24 (5): 620-630.

  9. Margitta Retz, Sachdev S. Sidhu, Jan Lehmann, Hirokazu Tamamura, Nobutaka Fujii & Carol Basbaum. New HIV-Drug Inhibits in Vitro Bladder Cancer Migration and Invasion Eur. Urol.. 2005; 48 (6): 1025-1030.

  10. Tamamura H, Sigano DM, Lewin NE, Peach ML, Nicklaus MC, Blumberg PM, Marquez VE. Conformationally constrained analogues of diacylglycerol (DAG). 23. Hydrophobic ligand-protein interactions versus ligand-lipid interactions of DAG-lactones with protein kinase C (PK-C). J Med Chem. 2004.09; 47 (20): 4858-4864. ( PubMed, DOI )

  11. Allen CD, Ansel KM, Low C, Lesley R, Tamamura H, Fujii N, Cyster JG. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol. 2004.09; 5 (9): 943-952. ( PubMed, DOI )

  12. Otaka A, Ueda S, Tomita K, Yano Y, Tamamura H, Matsuzaki K, Fujii N. Facile synthesis of membrane-embedded peptides utilizing lipid bilayer-assisted chemical ligation. Chem Commun (Camb). 2004.08; (15): 1722-1723. ( PubMed, DOI )

  13. Tamamura H, Fujisawa M, Hiramatsu K, Mizumoto M, Nakashima H, Yamamoto N, Otaka A, Fujii N. Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent. FEBS Lett. 2004.07; 569 (1-3): 99-104. ( PubMed, DOI )

  14. Tamamura H, Fujii N. Two orthogonal approaches to overcome multi-drug resistant HIV-1s: development of protease inhibitors and entry inhibitors based on CXCR4 antagonists. Curr Drug Targets Infect Disord. 2004.06; 4 (2): 103-110. ( PubMed )

  15. Yamamoto N, Yang R, Yoshinaka Y, Amari S, Nakano T, Cinatl J, Rabenau H, Doerr HW, Hunsmann G, Otaka A, Tamamura H, Fujii N, Yamamoto N. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun. 2004.06; 318 (3): 719-725. ( PubMed, DOI )

  16. Peng H, Huang Y, Rose J, Erichsen D, Herek S, Fujii N, Tamamura H, Zheng J. Stromal cell-derived factor 1-mediated CXCR4 signaling in rat and human cortical neural progenitor cells. J Neurosci Res. 2004.04; 76 (1): 35-50. ( PubMed, DOI )

  17. Tamamura H, Mizumoto M, Hiramatsu K, Kusano S, Terakubo S, Yamamoto N, Trent JO, Wang Z, Peiper SC, Nakashima H, Otaka A, Fujii N. Topochemical exploration of potent compounds using retro-enantiomer libraries of cyclic pentapeptides. Org Biomol Chem. 2004.04; 2 (8): 1255-1257. ( PubMed, DOI )

  18. Otaka A, Watanabe J, Yukimasa A, Sasaki Y, Watanabe H, Kinoshita T, Oishi S, Tamamura H, Fujii N. SmI2-mediated reduction of gamma,gamma-difluoro-alpha,beta-enoates with application to the synthesis of functionalized (Z)-fluoroalkene-type dipeptide isosteres. J Org Chem. 2004.03; 69 (5): 1634-1645. ( PubMed, DOI )

  19. Tamamura H, Sigano DM, Lewin NE, Blumberg PM, Marquez VE. Conformationally constrained analogues of diacylglycerol. 20. The search for an elusive binding site on protein kinase C through relocation of the carbonyl pharmacophore along the sn-1 side chain of 1,2-diacylglycerol lactones. J Med Chem. 2004.01; 47 (3): 644-655. ( PubMed, DOI )

  20. Mori T, Doi R, Koizumi M, Toyoda E, Ito D, Kami K, Masui T, Fujimoto K, Tamamura H, Hiramatsu K, Fujii N, Imamura M. CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther. 2004.01; 3 (1): 29-37. ( PubMed )

< 前のページ - 次のページ >

このページの先頭へ▲